Laurus Labs Limited (LAURUSLABS.BO)
INR 579.2
(3.34%)
INR 579.2
(3.34%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 24.38 Billion INR | 23.83% |
| 2022 | 19.69 Billion INR | 15.76% |
| 2021 | 17.01 Billion INR | 18.69% |
| 2020 | 14.33 Billion INR | 32.99% |
| 2019 | 10.77 Billion INR | 4.33% |
| 2018 | 10.32 Billion INR | 5.74% |
| 2017 | 9.76 Billion INR | 16.39% |
| 2016 | 8.39 Billion INR | -17.3% |
| 2015 | 10.14 Billion INR | 30.27% |
| 2014 | 7.79 Billion INR | 47.63% |
| 2013 | 5.27 Billion INR | 81.88% |
| 2012 | 2.9 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.41 Billion INR | -94.19% |
| 2024 Q2 | 26.78 Billion INR | 1838.45% |
| 2023 Q4 | 24.38 Billion INR | 3530.82% |
| 2023 Q2 | 20.67 Billion INR | 4166.59% |
| 2023 Q3 | 671.6 Million INR | -96.75% |
| 2023 Q1 | 484.6 Million INR | -97.54% |
| 2023 FY | 24.38 Billion INR | 23.83% |
| 2022 Q2 | 20.44 Billion INR | 2592.9% |
| 2022 Q4 | 19.69 Billion INR | 3673.02% |
| 2022 FY | 19.69 Billion INR | 15.76% |
| 2022 Q1 | 759.4 Million INR | -95.54% |
| 2022 Q3 | 521.9 Million INR | -97.45% |
| 2021 Q2 | 17.26 Billion INR | 3462.22% |
| 2021 FY | 17.01 Billion INR | 18.69% |
| 2021 Q4 | 17.01 Billion INR | 4298.97% |
| 2021 Q3 | 386.7 Million INR | -97.76% |
| 2021 Q1 | 484.6 Million INR | -96.62% |
| 2020 Q4 | 14.33 Billion INR | 65344.29% |
| 2020 FY | 14.33 Billion INR | 32.99% |
| 2020 Q2 | 10.8 Billion INR | 62013.79% |
| 2020 Q3 | 21.9 Million INR | -99.8% |
| 2020 Q1 | 17.4 Million INR | -99.84% |
| 2019 Q4 | 10.77 Billion INR | 22199.4% |
| 2019 FY | 10.77 Billion INR | 4.33% |
| 2019 Q2 | 11.4 Billion INR | 37640.98% |
| 2019 Q1 | 30.21 Million INR | -99.71% |
| 2019 Q3 | 48.33 Million INR | -99.58% |
| 2018 Q3 | 91.25 Million INR | -99.23% |
| 2018 Q4 | 10.32 Billion INR | 11220.12% |
| 2018 FY | 10.32 Billion INR | 5.74% |
| 2018 Q1 | 30.57 Million INR | -99.69% |
| 2018 Q2 | 11.83 Billion INR | 38630.16% |
| 2017 Q2 | 10.42 Billion INR | 25384.38% |
| 2017 Q1 | 40.91 Million INR | -99.51% |
| 2017 Q3 | 54.76 Million INR | -99.47% |
| 2017 Q4 | 9.76 Billion INR | 17739.72% |
| 2017 FY | 9.76 Billion INR | 16.39% |
| 2016 Q2 | 11.1 Billion INR | 3760.18% |
| 2016 FY | 8.39 Billion INR | -17.3% |
| 2016 Q4 | 8.39 Billion INR | 0.0% |
| 2016 Q1 | 287.74 Million INR | 0.0% |
| 2015 FY | 10.14 Billion INR | 30.27% |
| 2014 FY | 7.79 Billion INR | 47.63% |
| 2013 FY | 5.27 Billion INR | 81.88% |
| 2012 FY | 2.9 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -530.761% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -560.239% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 957.809% |
| Granules India Limited | 9.28 Billion INR | -162.573% |
| Indoco Remedies Limited | 6.47 Billion INR | -276.521% |
| Achyut Healthcare Limited | -3.74 Million INR | 651050.347% |
| Ajanta Pharma Limited | -954.9 Million INR | 2653.629% |
| Alkem Laboratories Limited | -1.6 Billion INR | 1615.136% |
| Alpa Laboratories Limited | 35.36 Million INR | -68855.123% |
| Brooks Laboratories Limited | 49.48 Million INR | -49176.751% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 586.482% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -639.161% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 2206.202% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | -88.838% |
| Eris Lifesciences Limited | 13.8 Billion INR | -76.618% |
| FDC Limited | -57.75 Million INR | 42322.953% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 669.034% |
| Gufic Biosciences Limited | 3.19 Billion INR | -663.374% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 687.148% |
| Ipca Laboratories Limited | 11.41 Billion INR | -113.615% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 1854.376% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -1161.541% |
| Lasa Supergenerics Limited | 205.79 Million INR | -11748.746% |
| Lupin Limited | 17.19 Billion INR | -41.834% |
| Mankind Pharma Limited | -9.9 Billion INR | 346.111% |
| Medicamen Biotech Limited | 160.31 Million INR | -15110.335% |
| Medico Remedies Limited | 78.67 Million INR | -30893.302% |
| Megasoft Limited | 1.28 Billion INR | -1796.819% |
| NATCO Pharma Limited | -5.81 Billion INR | 519.195% |
| Piramal Pharma Limited | 42.27 Billion INR | 42.32% |
| RPG Life Sciences Limited | -364.7 Million INR | 6786.208% |
| Sigachi Industries Limited | 859.94 Million INR | -2735.587% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 133.648% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -16719.749% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -52667.956% |
| Unichem Laboratories Limited | 931.91 Million INR | -2516.609% |
| Wanbury Limited | 1.1 Billion INR | -2105.005% |
| Windlas Biotech Limited | -273.04 Million INR | 9030.779% |
| ZIM Laboratories Limited | 983.6 Million INR | -2379.107% |
| Zydus Lifesciences Limited | 3.91 Billion INR | -523.328% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 2689.148% |
| Divi's Laboratories Limited | -39.77 Billion INR | 161.314% |
| Hester Biosciences Limited | 2.29 Billion INR | -964.486% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 1138.526% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 9901.199% |
| Bal Pharma Limited | 1.26 Billion INR | -1829.832% |
| Strides Pharma Science Limited | 23.25 Billion INR | -4.848% |
| Venus Remedies Limited | -267.7 Million INR | 9208.928% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -833.596% |
| Nectar Lifesciences Limited | 6.15 Billion INR | -296.027% |
| Shilpa Medicare Limited | 9.06 Billion INR | -168.863% |
| Aarti Drugs Limited | 5.54 Billion INR | -339.489% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 2314.165% |
| Suven Life Sciences Limited | -1.63 Billion INR | 1593.516% |
| Ind-Swift Limited | 9.5 Billion INR | -156.448% |
| Valiant Laboratories Limited | -295.03 Million INR | 8365.07% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -764.334% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | -143.141% |
| Themis Medicare Limited | 764.96 Million INR | -3087.688% |
| Hikal Limited | 7.96 Billion INR | -206.07% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 23.391% |
| Sequent Scientific Limited | 4.17 Billion INR | -483.555% |
| Novartis India Limited | -5.89 Billion INR | 513.923% |
| Wockhardt Limited | 18.27 Billion INR | -33.468% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 9.927% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 132294.514% |
| Neuland Laboratories Limited | -214.05 Million INR | 11491.585% |
| Morepen Laboratories Limited | -231.17 Million INR | 10648.159% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -20213.898% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -2398.906% |